Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia

Proteomics

Volumn 9, Issue 5, 2009, Pages 1197-1206

  Su, Xiaodan ^a   Lucas, David M ^a   Zhang, Liwen ^a   Xu, Hua ^b   Zabrouskov, Vlad ^c   Davis, Melanie E ^a   Knapp, Amy R ^a   Young, Donn C ^a   Payne, Philip R O ^a   Parthun, Mark R ^a   Marcucci, Guido ^a   Grever, Michael R ^a   Byrd, John C ^a   Freitas, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Thermo Fisher Scientific   (United States)

Author keywords

Chronic lymphocytic leukemia; Histone; RPLC MS; Variant

Indexed keywords

BIOLOGICAL MARKER; HISTONE; HISTONE H2A; HISTONE H3;

ARTICLE; B LYMPHOCYTE; CHROMATIN; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE CLASSIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANIMALS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MASS SPECTROMETRY; PROTEIN ISOFORMS; REPRODUCIBILITY OF RESULTS;

EID: 63049112921     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800333     Document Type: Article

References (34)

1. Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., et al., The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004, 18, 1207-1214.
2. CLL Trialists' Collaborative Group, Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl. Cancer Inst. 1999, 91, 861-868.
3. Byrd, J. C., Rai, K., Peterson, B. L., Appelbaum, F. R., et al., Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105, 49-53.
4. Keating, M. J., O'Brien, S., Albitar, M., Lerner, S., et al., Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 4079-4088.
5. Kay, N. E., Geyer, S. M., Call, T. G., Shanafelt, T. D., et al., Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109, 405-411.
6. Byrd, J. C., Shinn, C., Ravi, R., Willis, C. R., et al., Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999, 94, 1401-1408.
7. Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94, 1840-1847.
8. Ghia, P., Stamatopoulos, K., Belessi, C., Moreno, C., et al., Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005, 105, 1678-1685.
9. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., Stevenson, F. K., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94, 1848-1854.
10. Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z., et al., CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99, 1023-1029.
11. Oscier, D. G., Gardiner, A. C., Mould, S. J., Glide, S., et al., Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002, 100, 1177-1184.
12. Chen, L., Widhopf, G., Huynh, L., Rassenti, L., et al., Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100, 4609-4614.
13. Ferrarini, M., Chiorazzi, N., Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Semin. Hematol. 2004, 41, 207-223.
14. Stilgenbauer, S., Sander, S., Bullinger, L., Benner, A., et al., Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007, 92, 1242-1245.
15. Shanafelt, T. D., Witzig, T. E., Fink, S. R., Jenkins, R. B., et al., Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J. Clin. Oncol. 2006, 24, 4634-4641.
16. Grever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., et al., Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J. Clin. Oncol. 2007, 25, 799-804.
17. Zhang, L., Freitas, M. A., Wickham, J., Parthun, M. R., et al., Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry. J. Am. Soc. Mass Spectrom. 2004, 15, 77-86.
18. Gonzalo, S., Jaco, I., Fraga, M. F., Chen, T., et al., DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol. 2006, 8, 416-424.
19. Barlesi, F., Giaccone, G., Gallegos-Ruiz, M. I., Loundou, A., et al., Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 4358-4364.
20. Seligson, D. B., Horvath, S., Shi, T., Yu, H., et al., Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435, 1262-1266.
21. Byrd, J. C., Shinn, C., Ravi, R., Willis, C. R., et al., Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999, 94, 1401-1408.
22. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., et al., National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87, 4990-4997.
23. Weitkamp, J. H., Crowe, J. E., Jr., Blood donor leukocyte reduction filters as a source of human B lymphocytes. Biotechniques 2001, 31, 464-466.
24. Su, X., Jacob, N. K., Amunugama, R., Lucas, D. M., et al., Liquid chromatography mass spectrometry profiling of histones. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 850, 440-454.
25. Bonenfant, D., Coulot, M., Towbin, H., Schindler, P., van Oostrum, J., Characterization of histones H2A and H2B variants and their post-translational modifications by mass spectrometry. Mol. Cell Proteomics 2006, 5, 541-552.
26. Boyne, M. T., 2nd, Pesavento, J. J., Mizzen, C. A., Kelleher, N. L., Precise characterization of human histones in the H2A gene family by top down mass spectrometry. J. Proteome Res. 2006, 5, 248-253.
27. Horn, D. M., Zubarev, R. A., McLafferty, F. W., Automated reduction and interpretation of high resolution electrospray mass spectra of large molecules. J. Am. Soc. Mass Spectrom. 2000, 11, 320-332.
28. Ren, C., Zhang, L., Freitas, M. A., Ghoshal, K., et al., Peptide mass mapping of acetylated isoforms of histone H4 from mouse lymphosarcoma cells treated with histone deacetylase (HDACs) inhibitors. J. Am. Soc. Mass Spectrom. 2005, 16, 1641-1653.
29. Su, X., Zhang, L., Lucas, D. M., Davis, M. E., et al., Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry. Anal. Biochem. 2007, 363, 22-34.
30. Zhang, L., Su, X., Liu, S., Knapp, A. R., et al., Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry. J. Proteome Res. 2007, 6, 81-88.
31. Peat, J., Barton, B., Medical Statistics: A Guide to Data Analysis and Critical Appraisal, Blackwell Publishing, Malden, Massachusets 2005.
32. Hripcsak, G., Rothschild, A., Agreement, the F-Measure, and reliability in information retrieval. J. Am. Med. Inform. Assoc. 2005, 12, 296-298.
33. Passam, F., Tachynopoulou, V., Skoumi, D., Tsompanakou, A., et al., Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach. Ann. Hematol. 2006, 85, 795-805.
34. Schwaenen, C., Nessling, M., Wessenddor, S., Salvi, T., et al., Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc. Natl. Acad. Sci. USA 2003, 10, 1039-1044.